H.B. Fuller has agreed the terms of a recommended cash acquisition of Advanced Medical Solutions Group, valuing the Winsford-based woundcare and tissue-healing specialist at approximately £715m on an enterprise value basis.
Under the proposed transaction, AMS shareholders would receive 285 pence in cash for each share. The offer values the issued and to be issued share capital of AMS at around £659m and follows earlier takeover interest in the company, including a previous approach from H.B. Fuller and earlier private equity interest that did not proceed to an offer.
AMS develops and manufactures tissue-healing technologies, with operations spanning woundcare, surgical products, and medical adhesives. The company has built a position in regulated healthcare markets where product performance, clinical acceptance, manufacturing control, and regulatory evidence all influence commercial value.
H.B. Fuller is a US-headquartered adhesives group with a long history across industrial and consumer adhesive markets. The acquisition would strengthen its medical adhesive technologies platform, adding a UK-listed manufacturer with product development capability, regulatory expertise, and an international commercial footprint.
The transaction reflects continuing consolidation in medical technology manufacturing. Healthcare product groups are seeking platforms that combine materials science, formulation expertise, regulatory knowledge, and production scale. Medical adhesives and woundcare products sit close to that convergence because performance depends on the interaction between chemistry, substrate design, biocompatibility, sterilisation, packaging, shelf life, and clinical usability.
AMS would move inside a larger global adhesives group with wider manufacturing and distribution resources. That could strengthen access to US, European, and international markets while supporting investment across product development, production capacity, and commercial expansion. It also shifts the company from AIM-listed independence into a larger corporate structure, with the familiar trade-off between shareholder value realisation and loss of standalone strategic control.
Woundcare and surgical products are not simple consumables. They require controlled materials, validated production processes, clean manufacturing environments, batch traceability, quality systems, clinical evidence, and post-market surveillance. Scaling those products internationally demands more than sales reach; it requires manufacturing consistency and regulatory discipline across different healthcare systems.
The deal also sits alongside wider UK medtech industrial activity. Sanner’s integration of Cambridge-based Springboard into its global medical device and healthcare packaging operations has shown how design, human factors, industrialisation, and manufacturing are being pulled closer together in regulated healthcare markets. That same pressure applies to woundcare, where product design and production route have to be aligned from the outset.
Medical adhesives are becoming more strategically important as healthcare moves towards less invasive treatment, faster recovery, and products that can support wound closure, tissue management, drug delivery, diagnostics, and device assembly. Adhesive performance in medical settings is constrained by skin compatibility, moisture, movement, sterilisation, packaging, and shelf-life requirements. Industrial adhesive expertise can help, but medical applications require a different quality and regulatory framework from general manufacturing markets.
AMS gives H.B. Fuller a platform in a sector with high entry barriers. Healthcare customers expect evidence, supply reliability, and product continuity. Once a product is approved, adopted, and written into clinical practice or procurement channels, switching can be slow and carefully controlled. That makes successful medical technologies attractive acquisition targets, particularly where the buyer already has complementary chemistry, manufacturing, or channel capability.
The UK dimension is also significant. Britain has a strong base of medtech design, specialist manufacturing, contract development, precision machining, electronics, diagnostics, and healthcare materials companies. Many remain relatively small compared with global healthcare and life science groups. Acquisitions by larger overseas buyers can give those companies scale, but they also raise familiar questions about where future investment, decision-making, and high-value manufacturing activity will sit.
AMS directors intend to recommend the acquisition to shareholders, subject to the usual transaction conditions. If completed, the deal would be one of the larger UK medtech-related transactions of 2026 and would give H.B. Fuller a stronger position in medical adhesives at a time when healthcare materials are drawing attention from industrial groups looking for higher-margin, more regulated growth markets.
The acquisition marks another example of specialist UK healthcare manufacturing capability being drawn into larger international platforms, where clinical performance, materials science, regulatory control, and production scale increasingly determine competitive position.
